Physiological Pacing - Quo Vadis?

Author(s): Uwe K. H. Wiegand, Frank Bode, Heribert Schunkert

Journal Name: Current Cardiology Reviews

Volume 1 , Issue 3 , 2005

Become EABM
Become Reviewer
Call for Editor


Dual chamber pacemaker therapy was considered to be the optimal treatment for most patients with symptomatic bradycardias. During the last decade, the percentage of dual chamber pacing increased to more than 60% in the United States and Western Europe. Yet, recent multicenter trials (CTOPP, MOST, UKPACE) on dual chamber pacemaker therapy failed to demonstrate a clear prognostic advantage compared to single chamber ventricular pacing. Moreover, clinical benefits of dual chamber pacing like a lower incidence of atrial arrhythmias, a reduction of hospitalization for heart failure or quality of life improvements were lower than expected or even absent. This article discusses the above mentioned studies and their limitations, reviews the increasing evidence for avoiding right (apical) ventricular stimulation and presents current approaches to differential pacemaker therapy.

Keywords: AV synchronous pacing, heart failure, PACEMAKER SYNDROME, atrial fibrillation, IMPLANTATION

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [225 - 230]
Pages: 6
DOI: 10.2174/157340305774574116
Price: $65

Article Metrics

PDF: 2